Clinical and Translational Gastroenterology最新文献

{"title":"Impact of Short Duration FODMAP Restriction on Breath Gases and Gastrointestinal Symptoms.","authors":"Mythili P Pathipati, Aonghus Shortt, Claire Shortt, Barry McBride, Lorcan O'Rourke, Robert Burke, William D Chey, Lin Chang, Kyle Staller","doi":"10.14309/ctg.0000000000000886","DOIUrl":"10.14309/ctg.0000000000000886","url":null,"abstract":"<p><strong>Introduction: </strong>Irritable bowel syndrome symptoms are thought to relate in part to the accumulation of luminal gases after ingestion of fermentable carbohydrates (i.e., fermentable oligosaccharides, disaccharides and monosaccharides, and polyols [FODMAPs]). To understand this relationship, participants monitored breath hydrogen (H 2 ) and methane (CH 4 ) levels using an at-home breath analysis device and recorded symptoms and meals in real-time using the associated app.</p><p><strong>Methods: </strong>We studied 1,984 users from July 2021 to April 2025. Participants first completed a baseline week on their habitual diet, followed by a one-week low FODMAP diet (Reset), with continued tracking of meals, symptoms, and postprandial H 2 and CH 4 levels. Breath H 2 and CH 4 were measured in parts per million, and area under the curve was calculated to assess gas production during typical waking hours. Participants recorded dietary intake and gastrointestinal symptoms after meals (i.e., nonfasting).</p><p><strong>Results: </strong>Breath H 2 , CH 4 , and gastrointestinal symptoms (bloating, abdominal pain, and flatulence) were significantly reduced after FODMAP restriction (all P < 0.0001). Both mild/absent and moderate/severe symptom groups showed significant improvements in symptoms with greater absolute reductions seen in the moderate/severe group. Exhaled gas levels, particularly H 2 , exhibited diurnal variation corresponding to mealtimes and symptom patterns.</p><p><strong>Discussion: </strong>This study suggests that breath H 2 and CH 4 may be influenced by short-term dietary changes and could be a useful biomarker of response to FODMAP restriction. Future studies should investigate whether nonfasting breath H 2 and CH 4 levels, in response to habitual dietary intake, is predictive of response to the low-FODMAP diet.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery in the Treatment of Rectal Neuroendocrine Tumors: Systematic Review and Meta-Analysis of the Observational Studies.","authors":"Krzysztof Dąbkowski, Karolina Skonieczna-Żydecka, Katarzyna Gaweł, Wojciech Marlicz, Piotr Szredzki, Andrzej Białek","doi":"10.14309/ctg.0000000000000882","DOIUrl":"10.14309/ctg.0000000000000882","url":null,"abstract":"<p><strong>Introduction: </strong>Rectal neuroendocrine tumors (rNETs) are subepithelial lesions with potential of malignancy. Despite the guidelines recommending that rNETs measuring 10-20 mm should be removed either endoscopic submucosal dissection (ESD) or transanal endoscopic microsurgery (TEM), the management with these entities is still a clinical dilemma. We performed a meta-analysis to compare ESD and TEM regarding method effectiveness and safety in the treatment of rNETs.</p><p><strong>Methods: </strong>PubMed/MEDLINE/Embase/EBSCO/CINAHL was searched up for observational studies analyzing the efficacy and safety of both methods in the treatment of rNETs.</p><p><strong>Results: </strong>A total of 59 observational studies with a total of n = 2,804 participants were included. In a subgroup analysis, we demonstrated that the R0 resection rate was significantly ( P = 0.002) lower for ESD (rate: 0.854) than for TEM (0.924). The recurrence rate differed significantly ( P = 0.008); the lowest (event rate [ER] = 0.015) was found for ESD and the highest for TEM (ER = 0.035). The overall bleeding rate was 0.046 and perforation rate was 0.023 and no significant differences ( P = 0.274 for bleeding, P = 0.808 for perforation) were found by intervention type. The rate of other complications (wound dehiscence, soilage, incontinence, rectovaginal fistula, pelvic pain, retroperitoneal emphysema, coagulation syndrome) was significantly ( P = 0.000) higher for TEM (ER = 0.107) than ESD (ER = 0.013). We also included 4 comparative studies with 490 patients. Using random-effects analysis, we found that the risk ratio for R0 resection was approximately 10% lower for ESD. Our analysis showed significantly greater size ( P = 0.01) and follow-up ( P = 0.03) in the group treated with TEM.</p><p><strong>Discussion: </strong>The efficacy of TEM is higher than ESD with a higher risk of complications in this method. Lesions with a greater size are treated with TEM, and recurrence rate is greater for this procedure. Long follow-up is needed after the treatment of rNETs to detect the recurrence early.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Metabolites of One-Carbon Metabolism Are Associated With Esophageal Adenocarcinoma in a Population-Based Study.","authors":"Shailja C Shah, Maria Alejandra H Diaz, Xiangzhu Zhu, Teodoro Bottiglieri, Chang Yu, Lesley A Anderson, Helen G Coleman, Martha J Shrubsole","doi":"10.14309/ctg.0000000000000879","DOIUrl":"10.14309/ctg.0000000000000879","url":null,"abstract":"<p><strong>Introduction: </strong>Esophageal adenocarcinoma (EAC) develops through histopathological stages, including Barrett's esophagus (BE). We analyzed the associations between plasma levels of one-carbon metabolism factors and risks of long-segment BE or EAC.</p><p><strong>Methods: </strong>Plasma levels were measured from an Irish population-based case-control study (Factors INfluencing the Barrett Adenocarcinoma Relationship study; 204 long-segment BE cases, 211 EAC cases, and 251 controls). A \"methyl replete score\" was derived by assigning a score of 0 (<median) or 1 (>median) to the levels of 3 dietary methyl donors (methionine, choline, and betaine) and summing across the metabolites. Multinomial logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between EAC or BE and sex-specific quartiles or score using the lowest level as the reference category and adjusted for potential confounders.</p><p><strong>Results: </strong>Highest methionine, betaine, vitamin B6, and choline levels were all associated with 62%-82% reduced risks of EAC ( Ptrends < 0.001). Conversely, S-adenosylmethionine, S-adenosylmethionine/S-adenosylhomocysteine ratio, total homocysteine, and cystathionine were associated with a greater than 2-fold increased EAC risk. A higher methyl replete score was associated with reduced EAC risk (OR 0.33; 95% CI 0.16-0.66). The highest vs lowest plasma methionine levels were borderline statistically significantly associated with long-segment BE (OR 0.55; 95% CI 0.28-1.07), but all other associations were null.</p><p><strong>Discussion: </strong>Several biomarkers of one-carbon metabolism are associated with EAC risk, particularly markers of dietary methyl group donors. Future studies to replicate and prospectively evaluate these markers are warranted.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems.","authors":"Robert J Wong, Patricia D Jones, Bolin Niu, Paulo Pinheiro, Mae Thamer, Onkar Kshirsagar, Yi Zhang, Ronnie Fass, George Therapondos, Amit G Singal, Mandana Khalili","doi":"10.14309/ctg.0000000000000877","DOIUrl":"10.14309/ctg.0000000000000877","url":null,"abstract":"<p><strong>Introduction: </strong>Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is associated with improved patient outcomes. We aim to evaluate real-world utilization of HCC surveillance among safety-net populations with cirrhosis.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of adults with cirrhosis across 4 safety-net health systems from March 1, 2017, to February 28, 2022. Receipt of abdominal imaging with ultrasound, computed tomography, or magnetic resonance imaging and the corresponding ICD-9-CM / ICD-10-CM diagnosis codes at 6 months and 12 months were used to assess HCC surveillance.</p><p><strong>Results: </strong>Among 14,556 patients with cirrhosis (61.8% male, 73.0% non-White ethnic minorities, 54.4% with Medicaid or indigent care/uninsured), 70.9% and 78.1% received abdominal imaging agnostic to indication within 6 months and 12 months, respectively. When evaluating the receipt of abdominal imaging with a specific indication for HCC surveillance, 29.1% and 34.0% of patients received surveillance within 6 months and 12 months, respectively. On adjusted multivariable regression, greater odds of HCC surveillance were observed in older patients, ethnic minorities, and those with commercial insurance. Lower odds of HCC surveillance were observed in patients with indigent care (vs Medicare: odds ratio [OR] 0.85, 95% confidence interval [CI] 0.72-1.00), drug use (OR 0.63, 95% CI 0.55-0.71), and concurrent mental health/psychiatric diagnoses (OR 0.88, 95% CI 0.80-0.97).</p><p><strong>Discussion: </strong>Among a multicenter safety-net cohort of patients with cirrhosis, fewer than 30% received HCC surveillance within 6 months. While greater proportions received abdominal imaging agnostic to indication, the clinical benefit of these examinations for HCC surveillance may be limited because of concerns with abbreviated protocols, quality, and interpretation.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00877"},"PeriodicalIF":3.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Endoscopic Gastric Remodeling on Gastroesophageal Reflux Disease.","authors":"Pichamol Jirapinyo, David Leung, Walter W Chan, Christopher C Thompson","doi":"10.14309/ctg.0000000000000867","DOIUrl":"10.14309/ctg.0000000000000867","url":null,"abstract":"<p><strong>Introduction: </strong>Sleeve gastrectomy is associated with an increased incidence of gastroesophageal reflux disease (GERD). By contrast, the impact of endoscopic gastric remodeling (EGR) on GERD symptoms remains unclear.</p><p><strong>Methods: </strong>This prospective study included patients who underwent EGR and completed validated GERD-related patient-reported outcome questionnaires at baseline and 12 months postprocedure.</p><p><strong>Results: </strong>Fifty patients were included. At 12 months post-EGR, both GERD questionnaire and Reflux Symptom Index scores significantly improved. Proton-pump inhibitor use decreased from 38% at baseline to 20% at 12 months ( P = 0.047). The presence of a hiatal hernia at baseline was associated with greater symptom improvement.</p><p><strong>Discussion: </strong>EGR improves both typical and atypical GERD symptoms and reduces proton-pump inhibitor dependence. It may represent a preferable treatment option for patients with obesity and concomitant GERD.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00867"},"PeriodicalIF":3.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of High-Density Lipoprotein Cholesterol-Based Inflammatory Markers With MASLD and Significant Liver Fibrosis in US Adults: Insights From NHANES 2017-2020.","authors":"Shuangzhen Jia, Xiaolin Ye, Yan Kong, Zhaoxia Wang, Jie Wu","doi":"10.14309/ctg.0000000000000873","DOIUrl":"10.14309/ctg.0000000000000873","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic inflammation and lipid metabolism disturbances are important hallmarks of the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to explore the association of lymphocyte-high-density lipoprotein-cholesterol ratio (LHR), monocyte-HDL-C ratio (MHR), neutrophil-HDL-C ratio (NHR), and platelet-HDL-C ratio (PHR) with MASLD and significant liver fibrosis using NHANES 2017-2020 data.</p><p><strong>Methods: </strong>LHR, MHR, NHR, and PHR were calculated based on complete blood count parameters and serum HDL-C. MASLD and liver fibrosis were diagnosed based on transient elastography. Multivariate logistic regression analyses were used to explore these associations, and receiver operating characteristic was used to compare the predictive power of these markers.</p><p><strong>Results: </strong>A total of 8,341 participants were included, and the prevalence of MASLD and significant liver fibrosis was 45.1% and 11.57%, respectively. In fully adjusted models, log-transformed LHR, MHR, NHR, and PHR were positively associated with the odds of MASLD (odds ratio 1.853, 1.685, 1.470, and 1.879, respectively) and significant liver fibrosis (odds ratio 1.570, 1.425, 1.396, and 1.384, respectively) (all P < 0.05). Most of these associations were nonlinear, and significant positive correlations existed only after their respective inflection points. The association of LHR with significant liver fibrosis was more pronounced in men. Receiver operating characteristic analysis showed that LHR/NHR was superior in predicting MASLD, whereas MHR/NHR distinguished significant liver fibrosis better than other markers.</p><p><strong>Discussion: </strong>LHR, MHR, NHR, and PHR were independently associated with MASLD and liver fibrosis in US adults and may serve as emerging predictors. Future cohort studies are needed to confirm these findings and explore clinical predictive value.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00873"},"PeriodicalIF":3.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Full-Thickness Resection vs Submucosal Tunneling Endoscopic Resection for Gastric Submucosal Tumors.","authors":"Shuxi Liu, Zhukai Chen, Lingnan He, Aiping Xu, Zehua Zhang, Xiaojing Du, Shuangzhu Yang, Haibing Zhang, Li Zhang, Jingjing Lian, Meidong Xu, Tao Chen","doi":"10.14309/ctg.0000000000000869","DOIUrl":"10.14309/ctg.0000000000000869","url":null,"abstract":"<p><strong>Introduction: </strong>The new working submucosal tunnel space allows entry to deeper layers of the luminal wall or even entirely outside the gastrointestinal tract for the treatment of submucosal tumors. Based on this concept, we developed submucosal tunneling endoscopic resection (STER). Here, we compared the clinical outcomes between exposed endoscopic full-thickness resection (EFTR) and STER (nonexposed EFTR) and analyzed the efficacy and safety of Natural Orifice Transluminal Endoscopic Surgery (NOTES) based on STER for extra-gastrointestinal stromal tumors (EGISTs).</p><p><strong>Methods: </strong>Sixty consecutive patients with tumors in the lesser curvature of the stomach corpus were enrolled from July 2019 to December 2023. Data on clinicopathologic features, treatment results, and follow-up outcomes were collected and analyzed retrospectively.</p><p><strong>Results: </strong>Among the 60 patients, 31 patients underwent EFTR and 29 patients underwent STER. The EFTR group had a shorter procedure time ( P = 0.016) but a longer postoperative hospital stay ( P = 0.004) than the STER group. Tumor size > 2 cm and endoloop-clips suture were significantly associated with long-time procedure. NOTES based on STER was successful for EGISTs. Follow-up data from 6 to 60 months was collected with no loss. All patients were free from local recurrence and distant metastasis during the study period.</p><p><strong>Conclusions: </strong>Although the procedure time of STER is longer than that of EFTR, the postoperative hospital stay is shorter. Tumor size > 2 cm and use of endoloop-clips suture are significantly associated with long-time procedure. In addition, STER-based NOTES is a promising and safe methodology for the resection of EGISTs.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00869"},"PeriodicalIF":3.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PAMORAs in Opioid-Induced Constipation: Are We Following the Guidelines?","authors":"Katie Liu, Ariana Chen, Pranav Rajaram, Grayson Buning, Allen A Lee, Prashant Singh","doi":"10.14309/ctg.0000000000000876","DOIUrl":"10.14309/ctg.0000000000000876","url":null,"abstract":"<p><strong>Introduction: </strong>Peripherally acting u-opioid receptor antagonists (PAMORAs) are a safe and efficacious medication for treating opioid-induced constipation (OIC). This study evaluates the utilization of PAMORAs in patients with laxative-refractory OIC.</p><p><strong>Methods: </strong>Patients diagnosed with OIC from 2018 to 2023 were retrospectively identified at a tertiary care center. As recommended by the guidelines, patients were considered eligible for PAMORAs if they had failed at least 2 laxatives. Data on PAMORA prescription, demographics, clinical characteristics, and specialty of the managing provider were collected and analyzed using logistic regression and χ 2 analysis.</p><p><strong>Results: </strong>Of 281 patients diagnosed with OIC, 204 (73%) were eligible for a PAMORA, of which only 58 (28%) were prescribed one. There were no differences in demographic or clinical characteristics between those who were offered PAMORAs vs not. There was a significant difference in prescribing patterns based on provider specialty ( P < 0.001). Although gastrointestinal (GI) specialists saw less than half of the eligible patients, they offered PAMORAs at the highest proportion of 59% compared with non-GI specialists (13-16%) or primary care providers (18%). Multivariable logistic regression analysis showed 12.7-fold increased odds of being offered a PAMORA if the provider was from the GI department compared with all non-GI providers ( P < 0.001).</p><p><strong>Discussion: </strong>PAMORAs are underutilized in patients with OIC. GI prescribers offer PAMORAs at a higher proportion than other departments, and being seen in GI independently increases the likelihood of a patient receiving a PAMORA. This suggests that underutilization may be due to a lack of awareness and further education about PAMORAs is warranted.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00876"},"PeriodicalIF":3.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual and Reproductive Health of Patients With Early-Onset Colorectal Cancer.","authors":"Qiuping Jiang, Xing Xu, Pan Sun, Hongmei Hua","doi":"10.14309/ctg.0000000000000870","DOIUrl":"10.14309/ctg.0000000000000870","url":null,"abstract":"<p><p>Despite an overall decline in the incidence and mortality of colorectal cancer, diagnosed cases of colorectal cancer in young adults are rising significantly. As more and more young patients with colorectal cancer survive their primary disease, there is an increasing concern about reproductive health associated with primary treatment. There is considerable controversy in the available literature regarding the outcomes of pregnancies in patients with colorectal cancer, including maternal and fetal/neonatal outcomes. The most commonly reported adverse events in labor were cesarean section, pre-eclampsia, preterm birth, and neonatal complications associated with preterm birth. The purpose of this review was to summarize the unmet reproductive needs of patients with early-onset colorectal cancer, the gonadal toxicity and fertility effects of treatment on patients with early-onset colorectal cancer, and the maternal and fetal/neonatal effects of pregnancy, to optimize the overall prognosis of patients with early-onset colorectal cancer.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Trends and Projection of Liver Cancer Due to Nonalcoholic Steatohepatitis Among People Aged 55 Years and Older in China From 1990 to 2030: An Analysis of the Global Burden of Disease Study 2021.","authors":"Xi Yang, Xiaodan Yin, Huiqi Wu, Qiaomei Li, Yang Shen","doi":"10.14309/ctg.0000000000000872","DOIUrl":"10.14309/ctg.0000000000000872","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to characterize the temporal trends of liver cancer due to metabolic dysfunction-associated steatohepatitis (LCDMDS) burden in China during 1990-2021; evaluate their age, period, and cohort effects; and predict the disease burden for the next 9 years.</p><p><strong>Methods: </strong>Data were obtained from the Global Burden of Disease 2021 study. Joinpoint regression model was used to estimate the annual percentage change (APC) and the average APC of LCDMDS incidence and death rates, and the age-period-cohort analysis was used to estimate the age, period, and cohort effects. We extended the autoregressive integrated moving average (ARIMA) model to predict the disease burden of LCDMDS in 2022-2030.</p><p><strong>Results: </strong>From 1990 to 2021, the number of incidence cases, incidence rates, number of deaths, and death rates of LCDMDS among the Chinese population aged 55 years and older all increased significantly. The number of incidence cases rose from 2,763 to 9,018, the incidence rate increased from 1.93 per 100,000 to 2.38 per 100,000, the number of deaths increased from 2,942 to 8,721, and the death rate rose from 2.05 per 100,000 to 2.30 per 100,000. The average APCs of the incidence rate and death rate were 0.72% ( P < 0.05) and 0.42% ( P > 0.05), respectively. Taking the average levels of age, period, and cohort as reference, the relative risks of LCDMDS incidence and death first increased and then decreased with age, increased over time, and decreased with the development of the birth cohort. The prediction results of the ARIMA model showed that the number of incidence cases and deaths among the Chinese population aged 55 years and older will continue to increase from 2022 to 2030, whereas the incidence rate and death rate will show slight changes.</p><p><strong>Discussion: </strong>This study comprehensively explored the temporal trends of LCDMDS burden among Chinese aged 55 years and older from 1990 to 2021, revealing significant increases in incidence and mortality, as well as age, period, and cohort effects. ARIMA model projections show that the LCDMDS burden will continue to rise despite minor rate changes. Thus, immediate interventions such as early detection, public-health awareness-raising, and further research are urgently needed to relieve the LCDMDS burden in China.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00872"},"PeriodicalIF":3.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}